CP101

Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
CP Wire
Fri, 02/8/19 - 09:42 am
Finch Therapeutics
CP101
C. difficile
microbiome
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Fri, 02/8/19 - 09:37 am
Finch Therapeutics
CP101
C. difficile
microbiome
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Endpoints
Mon, 10/23/17 - 09:47 am
Takeda
Finch Therapeutics
Crestovo
C. difficile
microbiome
CP101